In this sense, PD-/PD-L1 blockade with Food and Drug Administration (FDA)-approved monoclonal antibodies such as anti-PD-1 (pembrolizumab, nivolimab, cemiplimab, camrelizumab), anti-PD-L1 (atezolizumab, durvalumab, avelumab), and CTLA-4 blockade with ipilimumab, were introduced in clinical trials for breast cancer in TNBC and have shown therapeutic potential [14]. Here, CD274 is linked to breast carcinoma.